To reach the next value inflection
LicenseRx asset brief
Use of VDAC inhibitor, VBIT4, as a Treatment for Lupus
Probability of Success
25% · grade C · Medium data confidence
Model PoS 25% (grade C, medium data confidence). Strongest signals: Data maturity, Modality feasibility. Biggest drag: IP position.
Data maturity (22%)
58
Preclinical; clinical reference.
IP position (16%)
30
Protection lapsed or abandoned -- verify freedom to operate.
Modality feasibility (14%)
82
Small molecule -- well-trodden regulatory and CMC path.
Indication pull (14%)
82
Immunology, Rare Disease -- active buyer appetite.
Competitive whitespace (12%)
80
Under-served segment.
Translational evidence (12%)
54
Public evidence mentions: clinical.
Licensing readiness (10%)
94
Listed as available for licensing; established tech-transfer office; 1 public source link(s).
Unlock the full strategic deep dive
Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.
View Operator access See what's included →